Cell Therapy News

Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.

Subscribe|Follow Us On

Impact of TP53 Alteration on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes

January 22, 2025

[Bone Marrow Transplantation] Scientists revealed the role of TP53 alterations in the prognosis of myelodysplastic syndrome (MDS) patients undergoing allogeneic hematopoietic stem cell transplantation.

The Maternal X Chromosome Affects Cognition and Brain Aging in Female Mice

January 22, 2025

[Nature] The authors tested whether skew towards an active maternal X (Xm) chromosome influenced the brain and body—and then delineated unique features of Xm neurons and paternal X neurons.

Triple Knockdown of CD11a, CD49d, and PSGL1 in T Cells Reduces CAR-T Cell Toxicity but Preserves Activity against Solid Tumors in Mice

January 22, 2025

[Science Translational Medicine] Researchers demonstrated that targeting the cell adhesion and migration molecules lymphocyte function–associated antigen 1 and very late activation antigen 4 with blocking antibodies reduced the on-target, off-tumor toxicity of CAR T cells in mice.

CD133+PD-L1+ Cancer Cells Confer Resistance to Adoptively Transferred Engineered Macrophage-Based Therapy in Melanoma

January 21, 2025

[Nature Communications] Researchers discovered a subpopulation of cancer cells with upregulated CD133 and programmed death-ligand 1 in mouse melanoma, resistant to the phagocytosis by the transferred macrophages.

Long-Term Safety of Lentiviral or Gammaretroviral Gene-Modified T Cell Therapies

January 21, 2025

[Nature Medicine] The authors evaluated safety outcomes in 783 patients over more than 2,200 total patient-years of observation from 38 T cell therapy trials.

Glut3 Overexpression Improves Environmental Glucose Uptake and Antitumor Efficacy of CAR-T Cells in Solid Tumors

January 20, 2025

[Journal for ImmunoTherapy of Cancer] Glucose transporters were detected and overexpressed in CAR-T cells. The impacts of glucose restriction on CAR-T cells were checked in vitro and in vivo.

PRDM1 Is a Key Regulator of the Natural Killer T–Cell Central Memory Program and Effector Function

January 20, 2025

[Cancer Immunology Research] To find regulators of natural killer T cells functional fitness, investigators developed a CRISPR/Cas9-based mutagenesis screen that employed a guide RNA library targeting 1,118 immune-related genes.

Mechanistic Determinants and Dynamics of cA6 Synthesis in Type III CRISPR-Cas Effector Complexes

January 17, 2025

[Nucleic Acids Research] Scientists used cryoelectron microscopy to visualize the mechanism of cA6 biosynthesis by the Csm effector complex from Enterococcus italicus.

Chimeric Antigen Receptor Macrophages (CAR-M) Sensitize HER2+ Solid Tumors to PD1 Blockade in Pre-Clinical Models

January 16, 2025

[Nature Communications] The authors developed clinically relevant fully immunocompetent syngeneic models to evaluate the potential for CAR-M to remodel the tumor microenvironment, induce T cell anti-tumor immunity, and sensitize solid tumors to PD1/PDL1 checkpoint inhibition.

Robust Genome Editing Activity and the Applications of Enhanced Miniature CRISPR-Cas12f1

January 16, 2025

[Nature Communications] Investigators developed enhanced Cas12f1, which exhibited gene editing activity similar to SpCas9 and AsCpf1, even in gene targets where previously improved Un1Cas12f1 variants showed low gene editing efficiency.

Multiplexed Inhibition of Immunosuppressive Genes with Cas13d for Combinatorial Cancer Immunotherapy

January 16, 2025

[Nature Biotechnology] Scientists described multiplex universal combinatorial immunotherapy via gene silencing, which used CRISPR–Cas13d to silence multiple endogenous immunosuppressive genes in the tumor microenvironment (TME), promoting TME remodeling and enhancing antitumor immunity.

Donor-Derived GD2-Specific CAR T Cells in Relapsed or Refractory Neuroblastoma

January 15, 2025

[Nature Medicine] Scientists presented a case series of five children with high-risk neuroblastoma refractory to more than three different lines of therapy who received ALLO_GD2-CART01 in a hospital exemption setting.

Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.